默沙东(MRK)四价HPV疫苗针对男性适应症获国家药监局上市批准

金吾财讯
08 Jan

金吾财讯 | 默沙东(MRK)正式宣布,四价HPV疫苗的多项新适应证已获得国家药品监督管理局的上市批准,适用于9~26岁男性接种。新适应证的获批,标志着默沙东佳达修®成为中国大陆地区首个且目前唯一获批、可适用于男性的HPV疫苗。 

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10